抗体-药物结合物:从传统构造到下一代构造的动态演变
Virginia Metrangolo1,2, Lars H Engelholm1,2
1The Finsen Laboratory, Rigshospitalet, DK-2200 Copenhagen, Denmark.
Cancers
|January 26, 2024
概括
抗体-药物联体 (ADCs) 提供有针对性的癌症治疗益处. 设计和交付方面的进步正在扩大其应用于更多癌症的范围,尽管存在毒性和耐药性等挑战.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学 是一个学科.
- 生物技术是生物技术.
背景情况:
- 抗体-药物联合体 (ADC) 是针对性癌症治疗的重大进展,为患者提供临床益处.
- 尽管由于其复杂性而存在最初的开发挑战,但最近的进展加速了ADC批准和后期临床开发.
研究的目的:
- 审查抗体与药物合物领域的最新趋势.
- 专注于结构设计,作用机制,以及它们对治疗型号的影响.
- 为了说明ADC从传统到创新的格式的演变,并讨论未来的方向.
主要方法:
- 关于ADC发展的最新趋势的文献综述.
- 分析结构设计,结合技术和链接策略.
- 检查作用机制及其对治疗结果的影响.
主要成果:
- 已批准的ADC和处于后期发展阶段的ADC的显著增加.
- 目标,有效载荷,结合方法和链接技术的多样化驱动下一代ADC.
- 确定关键障碍,包括毒性和耐药性.
结论:
- 下一代ADCs具有多样化的目标和有效载荷,为治疗难以治疗的癌症提供了新的希望.
- 在ADC设计和交付方面的持续创新对于克服当前的局限性至关重要.
- 未来的研究应该专注于改进ADC设计,以提高疗效,减轻耐药性和毒性.
相关概念视频
Phase II Conjugation Reactions: Overview
204
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
204
Antibody Actions
1.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K
Antibody Structure and Classes
913
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
913
Hybridoma Technology
14.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.7K
Antibody Structure
60.1K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
60.1K
Structure-Activity Relationships and Drug Design
721
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
721


